Chimerix (NASDAQ:CMRX) Stock Crosses Below Two Hundred Day Moving Average of $0.97

Shares of Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.97 and traded as low as $0.93. Chimerix shares last traded at $0.93, with a volume of 123,500 shares trading hands.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CMRX. StockNews.com raised shares of Chimerix from a "sell" rating to a "hold" rating in a research note on Wednesday, August 21st. Wedbush reissued an "outperform" rating and issued a $6.00 price target on shares of Chimerix in a report on Tuesday, August 13th. Finally, HC Wainwright restated a "buy" rating and issued a $11.00 price objective on shares of Chimerix in a research report on Wednesday, August 14th.

Chimerix Stock Performance

The stock has a market capitalization of $77.69 million, a price-to-earnings ratio of -0.98 and a beta of 1.20. The firm's fifty day simple moving average is $0.90 and its 200 day simple moving average is $0.97.

Chimerix (NASDAQ:CMRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, hitting analysts' consensus estimates of ($0.23). The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.26 million. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 46.35%. During the same period last year, the business posted ($0.21) earnings per share. Analysts forecast that Chimerix, Inc. will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Chimerix

Large investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in Chimerix during the 2nd quarter worth about $137,000. Acadian Asset Management LLC boosted its position in Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company's stock valued at $2,304,000 after purchasing an additional 291,981 shares during the last quarter. Koshinski Asset Management Inc. bought a new position in Chimerix in the first quarter valued at approximately $42,000. Marquette Asset Management LLC increased its position in shares of Chimerix by 24.3% during the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company's stock worth $123,000 after purchasing an additional 22,709 shares during the last quarter. Finally, Pale Fire Capital SE raised its stake in shares of Chimerix by 113.6% during the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company's stock worth $203,000 after purchasing an additional 112,318 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.